GeneNews Announces Issuance of Second Foundational U.S. Patent for Sentinel Principle® Technology
Want to listen to this article for FREE?
Complete the form below to unlock access to ALL audio articles.
Read time: Less than a minute
GeneNews Limited has announced that it has been granted a second U.S. patent for its core platform technology, the Sentinel Principle®. U.S. Patent No. 7,662,558, entitled "Method of profiling gene expression in a human subject."
The patent covers the application of the Sentinel Principle® in any health management context, including diagnosis, staging of disease, drug testing, monitoring response to treatment and biomarker screening.
"We believe that the Sentinel Principle® has the potential to change the way that medicine is currently practiced," said Gailina Liew, President & Chief Operating Officer of GeneNews.
"The issuance of this second U.S. patent significantly expands the scope of protection for this ground-breaking approach to identify clinically actionable biomarkers. It also enhances GeneNews' ability to realize additional commercial value through potential licensing arrangements, the pending issuance of additional patents which cover biomarker panels for specific clinical indications, and the continued development of our own pipeline of 'Sentry' products," Liew said.
The Sentinel Principle®, a platform technology discovered and developed by GeneNews, is based on the concept that all clinical conditions and body states, including those resulting from disease or in response to treatment, generate characteristic gene expression signatures in the blood as a result of the constant and dynamic physiological interaction of blood with the cells, tissues and organs of the human body. This technology is the basis of GeneNews' initial product, ColonSentry™.
The patent covers the application of the Sentinel Principle® in any health management context, including diagnosis, staging of disease, drug testing, monitoring response to treatment and biomarker screening.
"We believe that the Sentinel Principle® has the potential to change the way that medicine is currently practiced," said Gailina Liew, President & Chief Operating Officer of GeneNews.
"The issuance of this second U.S. patent significantly expands the scope of protection for this ground-breaking approach to identify clinically actionable biomarkers. It also enhances GeneNews' ability to realize additional commercial value through potential licensing arrangements, the pending issuance of additional patents which cover biomarker panels for specific clinical indications, and the continued development of our own pipeline of 'Sentry' products," Liew said.
The Sentinel Principle®, a platform technology discovered and developed by GeneNews, is based on the concept that all clinical conditions and body states, including those resulting from disease or in response to treatment, generate characteristic gene expression signatures in the blood as a result of the constant and dynamic physiological interaction of blood with the cells, tissues and organs of the human body. This technology is the basis of GeneNews' initial product, ColonSentry™.
